Annexon Inc GA Update Call Transcript
Hello and welcome to Annexon's conference call. (Operator Instructions) Please be advised that this call is being recorded at Annexon's request. I would now like to turn the call over to Lori Murray, Senior Vice President, Investor Relations and Corporate Communications. You may begin.
Thank you, Jonathan, and good afternoon. Earlier today we issued a press release outlining topline data from our ARCHER Phase 2 clinical trial evaluating ANX007 in patients with geographic atrophy.
The press release and the slides to which we'll refer are available under the Events and Presentations page within the Investors section of our website.
On the call with me today is our CEO, Douglas Love; as well as our Chief Innovation Officer, Dr. Ted Yednock; and our VP and Head of ophthalmology, Dr. Donald Fong. In addition, we are delighted to have Dr. Charles Wykoff join us for the Q&A session. Dr. Wykoff is the Director of Research at the Retina Consultants of Texas and an investigator in
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |